Michael H. Malim

Active 1985–2025

Also published as
Michael H Malim
134
Papers
31,451
Citations
92
h-index
131
i10-index

Citations

Citations per year for Michael H. Malim1967: 1 citations1979: 1 citations1984: 1 citations1986: 2 citations1987: 9 citations1988: 13 citations1989: 60 citations1990: 147 citations1991: 166 citations1992: 144 citations1993: 115 citations1994: 133 citations1995: 123 citations1996: 137 citations1997: 126 citations1998: 209 citations1999: 221 citations2000: 162 citations2001: 176 citations2002: 196 citations2003: 232 citations2004: 301 citations2005: 265 citations2006: 321 citations2007: 288 citations2008: 317 citations2009: 231 citations2010: 280 citations2011: 164 citations2012: 265 citations2013: 242 citations2014: 154 citations2015: 177 citations2016: 174 citations2017: 125 citations2018: 114 citations2019: 486 citations2020: 686 citations2021: 1,219 citations2022: 782 citations2023: 361 citations2024: 468 citations2025: 152 citations2026: 1 citations1968–1978: no citations, so these years are not shown1980–1983: no citations, so these years are not shown1985: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,408 citing papers, 36.6% of this breakdownUnited Kingdom: 905 citing papers, 9.7% of this breakdownGermany: 541 citing papers, 5.8% of this breakdownFrance: 459 citing papers, 4.9% of this breakdownChina: 451 citing papers, 4.9% of this breakdownCanada: 393 citing papers, 4.2% of this breakdownItaly: 301 citing papers, 3.2% of this breakdownAustralia: 218 citing papers, 2.4% of this breakdownJapan: 216 citing papers, 2.3% of this breakdownSwitzerland: 207 citing papers, 2.2% of this breakdownNetherlands: 179 citing papers, 1.9% of this breakdownSpain: 171 citing papers, 1.9% of this breakdown
0%36.6%Other 20%

Fields

  • Medicine36%
  • Immunology and Microbiology35.9%
  • Biochemistry, Genetics and Molecular Biology23.1%
  • Agricultural and Biological Sciences2.3%
  • Neuroscience0.5%
  • Mathematics0.5%
  • Other1.7%

Topics

  • HIV Research and Treatment11.6%
  • SARS-CoV-2 and COVID-19 Research7.8%
  • COVID-19 Clinical Research Studies5.3%
  • HIV/AIDS drug development and treatment4.6%
  • Immune Cell Function and Interaction3.7%
  • RNA Research and Splicing3.1%
  • Other63.9%

Coauthors

All papers

Open in search
  1. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia

    Authors: , , , , , , , , , , , , , , , , , , , - Nature 2021 cited by 440

  2. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

    Authors: , , , - Nature 2002 cited by 2,323

  3. The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID symptom study biobank prospective cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - EClinicalMedicine 2023 cited by 96

  4. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lorcan O’Connell, Geraldine O’Hara, Eithne MacMahon, Sam Douthwaite, Gaia Nebbia, Rahul Batra, Rocío T. Martínez-Nuñez, Manu Shankar‐Hari, Jonathan D. Edgeworth, Stuart J. D. Neil, Michael H. Malim, Katie J. Doores - Nature Microbiology 2020 cited by 1,384

  5. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection

    Authors: , , , , , , , , , - Nature 2013 cited by 570

  6. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection

    Authors: , , , , , , , , , , , , , - Nature Medicine 2020 cited by 436

  7. Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein

    Authors: , , , , , , , , , , , , - Nature Communications 2023 cited by 84

  8. Persistent HIV-1 replication maintains the tissue reservoir during therapy

    Authors: , , , , , , , , , , , , , , , - Nature 2016 cited by 631

  9. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2021 cited by 167

  10. Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing γδ T cell biology

    Authors: , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 cited by 165

  11. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernard V. North, Ana Montes, Mark Harries, Anne Rigg, James Spicer, Michael H. Malim, Paul Fields, Piers Patten, Francesca Di Rosa, Sophie Papa, Timothy Tree, Katie J. Doores, Adrian Hayday, Sheeba Irshad - The Lancet Oncology 2021 cited by 612

  12. HIV Restriction Factors and Mechanisms of Evasion

    Authors: , - Cold Spring Harbor Perspectives in Medicine 2012 cited by 506

  13. SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eleni Nastouli, Marit J. van Gils, Peter B. Rosenthal, Massimo Pizzato, Myra O. McClure, Richard S. Tedder, George Kassiotis, Laura E. McCoy, Katie J. Doores, Peter Cherepanov - Science Advances 2021 cited by 161

  14. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA

    Authors: , , , , - Nature 1989 cited by 1,280

  15. The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry

    Authors: , , , , , , , , , - Nature Microbiology 2018 cited by 95

  16. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

    Authors: , , - Nature Medicine 2003 cited by 955

  17. Human Immunodeficiency Virus Type 1 Spinoculation Enhances Infection through Virus Binding

    Authors: , , - Journal of Virology 2000 cited by 669

  18. HIV-1 and interferons: who's interfering with whom?

    Authors: , , - Nature Reviews Microbiology 2015 cited by 277

  19. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael H. Malim, Katie J. Doores - Nature Microbiology 2021 cited by 116

  20. APOBEC proteins and intrinsic resistance to HIV-1 infection

    Authors: - Philosophical Transactions of the Royal Society B Biological Sciences 2008 cited by 275

  21. Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Microbe 2021 cited by 157

  22. ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition—implications for COVID-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Markku Laakso, Mario Falchi, Jordana T. Bell, Laura J. Scott, Karen L. Mohlke, Kerrin S. Small - International Journal of Obesity 2022 cited by 44

  23. THE HIV-1 REV PROTEIN

    Authors: , - Annual Review of Microbiology 1998 cited by 708

  24. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: Implications for HIV-1 latency

    Authors: , - Cell 1991 cited by 429